ProfileGDS5678 / 1451597_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 67% 66% 66% 65% 66% 70% 70% 67% 66% 66% 67% 65% 68% 66% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.127267
GSM967853U87-EV human glioblastoma xenograft - Control 23.9787866
GSM967854U87-EV human glioblastoma xenograft - Control 34.022766
GSM967855U87-EV human glioblastoma xenograft - Control 43.9125865
GSM967856U87-EV human glioblastoma xenograft - Control 53.9430466
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.3380370
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.3812370
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.0622467
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.9591466
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.9849866
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.0337767
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.9083465
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.1650368
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.0110866